NCT07035249View on ClinicalTrials.gov

DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

July 30, 2025

Study Completion Date

July 30, 2027

Conditions
DCSZ11Solid TumorsHNSCC
Interventions
DRUG

Low Dose DCSZ11

Patients will receive DCSZ11 at 600 mg every three weeks (Q3W).

DRUG

Medium Dose DCSZ11

Patients will receive DCSZ11 at 800 mg Q3W.

DRUG

High Dose DCSZ11

Patients will receive DCSZ11 at 1200 mg Q3W.

DRUG

Standard Treatment

The available standard treatment for head and neck cancer patients.

All Listed Sponsors
lead

West China Hospital

OTHER